Return to Search
EN
The management of Familial Mediterranean Fever (FMF) aims to enable the vast majority of patients to lead normal lives through early diagnosis and appropriate treatment. A balanced diet, regular exercise, weight control, and a healthy, stress-free lifestyle play a supportive role in managing disease-related pain and maintaining overall health.
The primary medication used in controlling FMF symptoms is Colchicine. Colchicine significantly reduces the frequency and severity of attacks and is critically important in preventing the development of amyloidosis. Its association with azoospermia has not yet been fully clarified.
Colchicine Dosage and Use:
Treatment usually lasts a lifetime. Dosage is adjusted according to age and the severity of symptoms. For children, the initial dose is determined by age and can be increased with growth; for adults, 1 mg/day is generally recommended. In more complex situations, such as frequent attacks or the presence of amyloidosis, higher doses of 2-2.5 mg/day can be administered under medical supervision, provided liver and kidney functions are normal. It is important for patients who have undergone kidney transplantation to continue colchicine treatment post-transplant. Colchicine does not need to be discontinued during pregnancy and breastfeeding. Children taking colchicine are advised to undergo blood and urine tests at least twice a year.
Side Effects and Management:
The most common side effects of colchicine are diarrhea, bloating, and abdominal cramps; diarrhea is particularly common with higher doses. For patients who discontinue the medication due to side effects, dividing the daily dose into two or three split doses may help reduce them. Colchicine should be used cautiously in combination with certain drugs like erythromycin (macrolide antibiotics) or statins (cholesterol medications), as it can rarely cause muscle weakness. Rare, serious side effects such as myelosuppression, hepatotoxicity, and neuropathy can also occur.
Colchicine Resistance and Alternative Therapies:
If the frequency or severity of attacks does not improve despite colchicine treatment at the maximum tolerated dose, or if acute phase reactant levels remain high between attacks, colchicine resistance should be considered. In such cases, different treatment options targeting inflammation, such as interleukin-1 (IL-1) blockers (e.g., anakinra) and TNF inhibitors, can be evaluated.
What is the treatment for Familial Mediterranean Fever?
The primary medication used in controlling FMF symptoms is Colchicine. Colchicine significantly reduces the frequency and severity of attacks and is critically important in preventing the development of amyloidosis. Its association with azoospermia has not yet been fully clarified.
Colchicine Dosage and Use:
Treatment usually lasts a lifetime. Dosage is adjusted according to age and the severity of symptoms. For children, the initial dose is determined by age and can be increased with growth; for adults, 1 mg/day is generally recommended. In more complex situations, such as frequent attacks or the presence of amyloidosis, higher doses of 2-2.5 mg/day can be administered under medical supervision, provided liver and kidney functions are normal. It is important for patients who have undergone kidney transplantation to continue colchicine treatment post-transplant. Colchicine does not need to be discontinued during pregnancy and breastfeeding. Children taking colchicine are advised to undergo blood and urine tests at least twice a year.
Side Effects and Management:
The most common side effects of colchicine are diarrhea, bloating, and abdominal cramps; diarrhea is particularly common with higher doses. For patients who discontinue the medication due to side effects, dividing the daily dose into two or three split doses may help reduce them. Colchicine should be used cautiously in combination with certain drugs like erythromycin (macrolide antibiotics) or statins (cholesterol medications), as it can rarely cause muscle weakness. Rare, serious side effects such as myelosuppression, hepatotoxicity, and neuropathy can also occur.
Colchicine Resistance and Alternative Therapies:
If the frequency or severity of attacks does not improve despite colchicine treatment at the maximum tolerated dose, or if acute phase reactant levels remain high between attacks, colchicine resistance should be considered. In such cases, different treatment options targeting inflammation, such as interleukin-1 (IL-1) blockers (e.g., anakinra) and TNF inhibitors, can be evaluated.